Tags

Type your tag names separated by a space and hit enter

[Patients with mild cognitive impairment and a reduced CSF Aβ₁₋₄₂ protein progress rapidly to Alzheimer's disease].
Neurologia. 2012 Jan; 27(1):28-33.N

Abstract

INTRODUCTION

Some studies have shown that CSF amyloid-beta 1-42 (Aβ₁₋₄₂), total tau (T-tau) and tau phosphorylated at threonine 181 (P-tau(181p)) proteins are useful diagnostic markers for distinguishing between clinically stable mild cognitive impairment (MCI) patients and those who will develop Alzheimeŕs disease (AD). Our objective was to test the ability of this technique to discriminate in our cohort of MCI patients, according to the clinical outcome, one year after the lumbar puncture.

MATERIAL AND METHODS

A total of 36 MCI patients were included from the local hospital memory clinic. Using INNO-BIA Alzbio-3 reagents from Innogenetics, we measured CSF Aβ₁₋₄₂, T-tau and P-tau(181p) proteins, and calculated the T-tau/Aβ₁₋₄₂ y P-tau(181p)/Aβ₁₋₄₂ ratios. This project was approved by the local ethics committee.

RESULTS

One year after the lumbar puncture, 14 MCI patients (38%) developed AD. These patients had lower Aβ₁₋₄₂ protein levels (285.3 vs 377 ng/ml, P<.02) and higher P-tau(181p)/Aβ₁₋₄₂ ratio (0,25 vs 0,16, p<.02) than the clinically stable patients.

CONCLUSIONS

Our MCI patients with lower Aβ₁₋₄₂ protein levels and an increased P-tau(181p) /Aβ₁₋₄₂ ratio progressed quickly to AD. These results may help to identify those MCI patients with a poorer prognosis.

Authors+Show Affiliations

Servicio de Neurología, Hospital General Universitario de Alicante, Alicante, España. monge jos@gva.esNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

spa

PubMed ID

21621878

Citation

Monge-Argilés, J A., et al. "[Patients With Mild Cognitive Impairment and a Reduced CSF Aβ₁₋₄₂ Protein Progress Rapidly to Alzheimer's Disease]." Neurologia (Barcelona, Spain), vol. 27, no. 1, 2012, pp. 28-33.
Monge-Argilés JA, Sánchez-Payá J, Muñoz-Ruiz C, et al. [Patients with mild cognitive impairment and a reduced CSF Aβ₁₋₄₂ protein progress rapidly to Alzheimer's disease]. Neurologia. 2012;27(1):28-33.
Monge-Argilés, J. A., Sánchez-Payá, J., Muñoz-Ruiz, C., Pampliega-Pérez, A., Gómez-López, M. J., Rodríguez Borja, E., Montoya-Gutiérrez, J., & Leiva-Santana, C. (2012). [Patients with mild cognitive impairment and a reduced CSF Aβ₁₋₄₂ protein progress rapidly to Alzheimer's disease]. Neurologia (Barcelona, Spain), 27(1), 28-33. https://doi.org/10.1016/j.nrl.2011.03.014
Monge-Argilés JA, et al. [Patients With Mild Cognitive Impairment and a Reduced CSF Aβ₁₋₄₂ Protein Progress Rapidly to Alzheimer's Disease]. Neurologia. 2012;27(1):28-33. PubMed PMID: 21621878.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Patients with mild cognitive impairment and a reduced CSF Aβ₁₋₄₂ protein progress rapidly to Alzheimer's disease]. AU - Monge-Argilés,J A, AU - Sánchez-Payá,J, AU - Muñoz-Ruiz,C, AU - Pampliega-Pérez,A, AU - Gómez-López,M J, AU - Rodríguez Borja,E, AU - Montoya-Gutiérrez,J, AU - Leiva-Santana,C, Y1 - 2011/05/31/ PY - 2010/12/18/received PY - 2011/03/21/revised PY - 2011/03/27/accepted PY - 2011/5/31/entrez PY - 2011/5/31/pubmed PY - 2012/8/28/medline SP - 28 EP - 33 JF - Neurologia (Barcelona, Spain) JO - Neurologia VL - 27 IS - 1 N2 - INTRODUCTION: Some studies have shown that CSF amyloid-beta 1-42 (Aβ₁₋₄₂), total tau (T-tau) and tau phosphorylated at threonine 181 (P-tau(181p)) proteins are useful diagnostic markers for distinguishing between clinically stable mild cognitive impairment (MCI) patients and those who will develop Alzheimeŕs disease (AD). Our objective was to test the ability of this technique to discriminate in our cohort of MCI patients, according to the clinical outcome, one year after the lumbar puncture. MATERIAL AND METHODS: A total of 36 MCI patients were included from the local hospital memory clinic. Using INNO-BIA Alzbio-3 reagents from Innogenetics, we measured CSF Aβ₁₋₄₂, T-tau and P-tau(181p) proteins, and calculated the T-tau/Aβ₁₋₄₂ y P-tau(181p)/Aβ₁₋₄₂ ratios. This project was approved by the local ethics committee. RESULTS: One year after the lumbar puncture, 14 MCI patients (38%) developed AD. These patients had lower Aβ₁₋₄₂ protein levels (285.3 vs 377 ng/ml, P<.02) and higher P-tau(181p)/Aβ₁₋₄₂ ratio (0,25 vs 0,16, p<.02) than the clinically stable patients. CONCLUSIONS: Our MCI patients with lower Aβ₁₋₄₂ protein levels and an increased P-tau(181p) /Aβ₁₋₄₂ ratio progressed quickly to AD. These results may help to identify those MCI patients with a poorer prognosis. SN - 1578-1968 UR - https://www.unboundmedicine.com/medline/citation/21621878/[Patients_with_mild_cognitive_impairment_and_a_reduced_CSF_Aβ₁₋₄₂_protein_progress_rapidly_to_Alzheimer's_disease]_ L2 - http://www.elsevier.es/en/linksolver/ft/pii/S0213-4853(11)00161-7 DB - PRIME DP - Unbound Medicine ER -